Trial · NCT01682759
Results by group16
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 16 of 16
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change From Baseline in Hemoglobin A1C at Week 54 | Omarigliptin | -0.30 | 95% Confidence Interval -0.39 to -0.21 | A1C (%) | |
| Change From Baseline in Hemoglobin A1C at Week 54 | Glimepiride | -0.48 | 95% Confidence Interval -0.57 to -0.39 | A1C (%) | |
| Percentage of Participants Who Experienced at Least One Adverse Event Excluding Data After Glycemic Rescue | Omarigliptin | 54.7 | Percentage of participants | ||
| Percentage of Participants Who Experienced at Least One Adverse Event Excluding Data After Glycemic Rescue | Glimepiride | 61.6 | Percentage of participants | ||
| Percentage of Participants Who Discontinued From the Study Due to an Adverse Event Excluding Data After Glycemic Rescue | Omarigliptin | 3.7 | Percentage of participants | ||
| Percentage of Participants Who Discontinued From the Study Due to an Adverse Event Excluding Data After Glycemic Rescue | Glimepiride | 2.7 | Percentage of participants | ||
| Change From Baseline in Fasting Plasma Glucose at Week 54 | Omarigliptin | -2.7 | 95% Confidence Interval -6.7 to 1.3 | mg/dL | |
| Change From Baseline in Fasting Plasma Glucose at Week 54 | Glimepiride | -8.3 | 95% Confidence Interval -12.4 to -4.3 | mg/dL | |
| Percentage of Participants Achieving a Hemoglobin A1C of <6.5% at Week 54 | Omarigliptin | 25.1 | 95% Confidence Interval 20.6 to 30.2 | Percentage of participants | |
| Percentage of Participants Achieving a Hemoglobin A1C of <6.5% at Week 54 | Glimepiride | 28.8 | 95% Confidence Interval 24.1 to 34.0 | Percentage of participants | |
| Percentage of Participants With an Adverse Event of Symptomatic Hypoglycemia Excluding Data After Glycemic Rescue | Omarigliptin | 5.3 | Percentage of participants | ||
| Percentage of Participants With an Adverse Event of Symptomatic Hypoglycemia Excluding Data After Glycemic Rescue | Glimepiride | 26.7 | Percentage of participants | ||
| Change From Baseline in Body Weight at Week 54 Excluding Data After Gylcemic Rescue | Omarigliptin | -0.4 | 95% Confidence Interval -0.8 to -0.0 | kg | |
| Change From Baseline in Body Weight at Week 54 Excluding Data After Gylcemic Rescue | Glimepiride | 1.5 | 95% Confidence Interval 1.1 to 1.9 | kg | |
| Percentage of Participants Achieving a Hemoglobin A1C of <7.0% at Week 54 | Omarigliptin | 47.7 | 95% Confidence Interval 42.3 to 53.1 | Percentage of participants | |
| Percentage of Participants Achieving a Hemoglobin A1C of <7.0% at Week 54 | Glimepiride | 58.0 | 95% Confidence Interval 52.7 to 63.1 | Percentage of participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01682759/results